FundaMental Pharma launches with EUR 10 million in Seed financing led by BGV and Thuja Capital to advance a First-in-Class neuroprotectant

November 17, 2022

Heidelberg, Germany – 17 November 2022 – FundaMental Pharma GmbH (“FundaMental”), a preclinical neuroscience company spun out of Heidelberg University, today announces that it has launched with EUR 10 million in seed financing led by BioGeneration Ventures (BGV) and Thuja Capital, with participation from other investors, including coparion and High-Tech Gründerfonds (HTGF).

Built on the pioneering research of Professor Hilmar Bading and Dr. Jing Yan published in Science[1], the founders of FundaMental have identified first-in-class small molecule inhibitors for treatment of a range of neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS) and Huntington’s Disease. FundaMental’s novel approach relies on separating the normal neuroprotective effect of synaptic glutamate from its neurotoxic extra-synaptic actions, which are eliminated by the inhibitors.

I am convinced that the successful development of FundaMental’s small molecule inhibitors will mark a milestone in neuropharmacology and possibly beyond. It has been a privilege to have worked with Professor Bading`s team since 2010 and to have put together such a strong leadership team. Having found visionary investors whose aims are aligned with the founder’s goals of stopping neurodegeneration, this vision can now become reality after many years of dedication and persistence.

Dr. Thomas Schulze, CEO and co-founder of FundaMental

It is probably no exaggeration to call the discovery of the new therapeutic principle of ‘inhibition of an extra-synaptic glutamate-activated death signaling complex’ a breakthrough in neuroscience. These inhibitors have the potential to revolutionize therapies for currently untreatable neurodegenerative diseases and offer hope to many affected and suffering patients.

Professor Hilmar Bading, Director of the Department of Neurobiology and the Interdisciplinary Center for Neurosciences at Heidelberg University and Co-Founder of FundaMental

In conjunction with the financing, FundaMental also announced several key senior management appointments as well as the Board of Directors of the company. Dr. Gabriele Hecker-Barth has joined as Chief Medical Officer and Dr. Jing Yan as Senior Director of Research. Dr. Keno Gutierrez of BGV and Dr. Michel Briejer of Thuja Capital, Professor Hilmar Bading and Dr. Thomas Schulze have been appointed to the company’s Board of Directors.

FundaMental’s novel therapeutics provide new hope to patients of ALS, Huntington’s disease and spinocerebellar ataxia 3, which remain devastating diseases that have an immense impact on the quality of patients’ lives. We are excited to invest and support the FundaMental team as they endeavor to make these molecules ready for the clinic.

Dr. Keno Gutierrez, new Chairman of FundaMental’s Board of Directors and Partner at BGV

Professor Bading and Dr. Yan have made a promising and important discovery, unlocking the possibility to inhibit glutamate neurotoxicity while leaving its physiologically important aspects unaffected. We are thrilled to be part of this venture with a mission to impact the lives of patients suffering from these neurodegenerative diseases.

Dr. Michel Briejer, Board Member and Managing Partner at Thuja Capital

The FundaMental Pharma team has achieved promising results with their interface inhibitors, which have the potential to open a new therapeutic window for the treatment of neurodegenerative diseases such as ALS. We are happy to have a consortium of reputable investors joining the company on its further journey towards success.

Niels Sharman, Investment Manager at HTGF


About FundaMental Pharma GmbH
FundaMental Pharma (“FundaMental”) is a neuroscience company, spun out of Heidelberg University, developing first-in-class small inhibitors for treatment of a range of neurodegenerative diseases. FundaMental scientists have discovered an entirely new class of drugs that safely counteract glutamate excitotoxicity, a common cause of neurodegeneration. While FundaMental current focus is on Amyotrophic Lateral Sclerosis (ALS) and Huntington’s Disease, the applicability of these molecules extend to a range of neurogenerative disorders such as dementia and aging-related memory loss. For more information, please visit:  www.fundamentalpharma.com

Contact
Dr. Thomas Schulze, CEO
Email: thomas.schulze@fundamentalpharma.com

About BGV
BioGeneration Ventures (BGV) is a venture capital company, with a focus on early-stage European biotech companies. The Company has a strong track record of significant financial returns through investing in innovations in healthcare and providing the expertise to build world-class companies.

BGV manages over EUR 225 million of funds investing in areas where true scientific innovations, the unmet medical need, and the potential to demonstrate a significant proof of concept all come together.

BGV strives to work with founding teams to mature science and build companies. The Company uses its experience to guide progress into clinical trials, ultimately leading to successful drug development and value realization for its investors. BGV applies its expertise in a rigorous process to select the most compelling opportunities with the best prospects for exit. BGV is based in Naarden, The Netherlands.
For more information, please visit:  www.biogenerationventures.com

Contact
Laura Asbjornsen, Head of Communications
Email: info@biogeneration.vc

Ashley Tapp, Sue Charles
Email: BGV@consilium-comms.com

About Thuja Capital
Thuja Capital Management (Thuja Capital) manages several venture capital funds aimed at building and scaling companies in the fields of (bio)pharmaceuticals, medtech and digital health. In addition to generating a financial return for its investors, Thuja’s investments aim to positively impact the health and well-being of patients. Thuja serves physicians and patients worldwide by providing capital and support to daring entrepreneurs with ground-breaking product concepts.
For more information, please visit www.thujacapital.com

Contact
Aartie Nanda
Email: an@thujacapital.com

About coparion
coparion provides venture capital to accelerate momentum and growth. With a current fund of EUR 275 million coparion has the means to do so. coparion supports entrepreneurial vision with know-how, but without intervening in daily business operations. Thanks to in-depth experience in venture capital and in building companies, the coparion team discerns potentials and opens up new perspectives. coparion only invests with co-investors. Investment focus is on German companies in the start-up and early growth phase. coparion is based in Cologne and Berlin.
For more information, please visit www.coparion.vc.

About High-Tech Gründerfonds
The seed investor High-Tech Gründerfonds (HTGF) finances tech start-ups with growth potential and has supported over 680 start-ups since 2005. With the launch of its fourth fund, HTGF now has over 1.3 billion euros under management. Its team of experienced investment managers and start-up experts support young companies with expertise, entrepreneurial spirit and passion. HTGF’s focus is on high-tech start-ups in the fields of digital tech, industrial tech, life sciences, chemistry and related business areas. To date, external investors have injected more than 4 billion euros of capital into the HTGF portfolio via more than 1,900 follow-on financing rounds. In addition, HTGF has already successfully sold shares in more than 160 companies.

Fund investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and the Fraunhofer-Gesellschaft along with over 40 companies from a wide range of industries.

Press Contact
Stefanie Grüter, Partner Communications & Relations
+49 228 82300188
s.grueter@htgf.de

Contact Investor
Niels Sharman, Investment Manager
+49 (0)228 82300 187
n.sharman@htgf.de


[1] Yan J. et al. Science. 2020 Oct 9;370(6513):eaay3302. doi: 10.1126/science.aay3302.

Jones S. Science (2020). https://doi.org/10.1126/science.abe2791

Stay up to date

Subscribe now and receive the latest press releases on investments and other news from High-Tech Gründerfonds. We inform you about important developments at HTGF and provide you with interesting news from our portfolio. Whether it’s a successful exit, a new exciting investment or HR news – you’ll be the first to know!

Press
16. May 2024

Caeli Wind, the digital platform for wind energy sites, secures €11 million in fresh capital in a Series A funding round.

Notion Capital, Santander Alternative Investments and existing investors provide the digital wind energy pioneer with growth capital for deeper value creation and international expansion. Berlin, London, Madrid (16 May 2024) – Caeli Wind, the platform for analysing and marketing wind energy locations founded by Ben Schlemmermeier and Heiko Bartels in 2022, announced today that it has secured €11 million in growth capital from international investors. The round was led by re
 
Press
7. May 2024

Automated renewable energy planning: Greentech startup everyone energy closes seed financing round

Berlin, 7 May 2024 – Berlin-based greentech startup everyone energy announces the successful closing of its seven-figure seed financing round. The round was led by High-Tech Gründerfonds (HTGF), one of Europe’s leading seed investors, and Cologne-based early-stage VC neoteq ventures. Founded in August 2021 by Céline Göhlich, Fabian Reetz and Florian Gmeiner, everyone energy has quickly established itself as a leading provider of white-label software for customized advisory serv